The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease”

 

Doylestown, PA. March 26, 2015- FCCDC is pleased to announce that it has been awarded a Phase 1 SBIR grant from the National Institutes of Health, entitled “Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease” (R43 DK105694).